[Recurrent aphthosis: safety of low dose thalidomide].

作者信息

Gil H, Perrin S, Dupond J-L, Meaux-Ruault N, Hafsaoui C, Limat S, Magy-Bertrand N

机构信息

Service de médecine interne, CHU Jean-Minjoz, 1, boulevard Fleming, 25000 Besançon, France.

出版信息

Rev Med Interne. 2010 Jun;31(6):403-5. doi: 10.1016/j.revmed.2009.12.008.

PURPOSE

Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed.

METHODS

Single-centre non-randomized retrospective open study.

RESULTS

Forty-seven patients were treated with thalidomide for recurrent aphthosis (41 patients) or Behçet disease (six patients). Remission was obtained with a dose of 25 mg daily. Discontinuation of treatment for side effects was not observed in this case series.

CONCLUSION

Low dose thalidomide below 50 mg daily is an effective and well tolerated treatment of aphthosis.